Icosapent ethyl: Eicosapentaenoic acid concentration and triglyceride-lowering effects across clinical studies
详细信息 查看全文
- 作者：Harold E. Bays ; MDa ; hbaysmd@aol.com" class="auth_mail" title="E-mail the corresponding author ; Christie M. Ballantyne ; MDb ; cmb@bcm.tmc.edu" class="auth_mail" title="E-mail the corresponding author ; Ralph T. Doyle Jr. ; BAc ; ralph.doyle@amarincorp.com" class="auth_mail" title="E-mail the corresponding author ; Rebecca A. Juliano ; PhDc ; rebecca.juliano@amarincorp.com" class="auth_mail" title="E-mail the corresponding author ; Sephy Philip ; RPh ; PharmDc ; sephy.philip@amarincorp.com" class="auth_mail" title="E-mail the corresponding author
- 关键词：Eicosapentaenoic acid ; Hypertriglyceridemia ; Icosapent ethyl ; Pharmacodynamics ; Triglycerides
- 刊名：Prostaglandins and Other Lipid Mediators
- 出版年：2016
- 出版时间：September 2016
- 年：2016
- 卷：125
- 期：Complete
- 页码：57-64
- 全文大小：1372 K
文摘
- m" id="list_lis0005">
- •
Icosapent ethyl exhibits dose-dependent and predictable PK/PD.
- •
EPA exposure and TG-lowering efficacy increase dose-dependently with icosapent ethyl.
- •
Plasma EPA was > 170 μg/mL with icosapent ethyl 4 g/day in patients with TGs ≥ 200 mg/dL.
- •
RBC EPA was > 70 μg/mL with icosapent ethyl 4 g/day in patients with TGs ≥ 200 mg/dL.